Subtopic Deep Dive
Molecular Subtypes of Clear Cell Renal Cell Carcinoma
Research Guide
What is Molecular Subtypes of Clear Cell Renal Cell Carcinoma?
Molecular subtypes of clear cell renal cell carcinoma (ccRCC) are genomic and transcriptomic classifications derived from comprehensive profiling to identify distinct tumor subgroups with varying prognoses and therapeutic responses.
Key studies like Wheeler et al. (2013) performed comprehensive molecular characterization of ccRCC, revealing frequent VHL mutations and mTOR pathway alterations (3433 citations). Chen et al. (2016) developed a multilevel genomics-based taxonomy classifying 894 RCCs into nine molecular subtypes using DNA methylation, copy number, RNA, and protein data (372 citations). Mitchell et al. (2018) traced evolutionary landmarks in ccRCC, linking subtype progression to clonal events (533 citations).
Why It Matters
Molecular subtyping guides precision medicine in ccRCC by matching therapies to specific alterations, such as mTOR inhibitors for pathway-activated subtypes (Wheeler et al., 2013). It addresses tumor heterogeneity, improving prognosis prediction beyond histologic classification, where subtype-specific features influence outcomes (Moch et al., 2000). Clinical guidelines integrate subtyping for treatment decisions in localized and advanced RCC (Escudier et al., 2019; Campbell et al., 2017).
Key Research Challenges
Tumor Heterogeneity Profiling
ccRCC exhibits intratumor heterogeneity, complicating subtype identification from single biopsies (Mitchell et al., 2018). Multi-region sequencing reveals evolving clones, but standardizes classification across datasets remain elusive. Integrating DNA, RNA, and protein levels adds complexity (Chen et al., 2016).
Therapeutic Response Correlation
Subtype-specific responses to TKIs and mTOR inhibitors vary, requiring validated predictors (Wheeler et al., 2013). Clinical trials like those for erdafitinib show FGFR-altered responses, but ccRCC subtype links need prospective data (Loriot et al., 2019). Prognosis differs by subtype, yet integration into TNM staging lags (Moch et al., 2000).
Scalable Classifier Development
Genomic classifiers demand large cohorts for reproducibility across platforms (Chen et al., 2016). VHL and ALK fusions define rare subtypes, but routine clinical adoption faces validation hurdles (Debelenko et al., 2010). Liquid biopsy approaches for non-invasive subtyping are emerging but unproven in ccRCC (Lone et al., 2022).
Essential Papers
Comprehensive molecular characterization of clear cell renal cell carcinoma
David A. Wheeler, Divya Kalra, Chad J. Creighton et al. · 2013 · Nature · 3.4K citations
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
Yohann Loriot, Andrea Necchi, Se Hoon Park et al. · 2019 · New England Journal of Medicine · 1.3K citations
The use of erdafitinib was associated with an objective tumor response in 40% of previously treated patients who had locally advanced and unresectable or metastatic urothelial carcinoma with <i>FGF...
Renal Mass and Localized Renal Cancer: AUA Guideline
Steven C. Campbell, Robert G. Uzzo, Mohamad E. Allaf et al. · 2017 · The Journal of Urology · 1.2K citations
Several factors should be considered during counseling/management of patients with clinically localized renal masses, including general health/comorbidities, oncologic potential of the mass, pertin...
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Bernard Escudier, Camillo Porta, Manuela Schmidinger et al. · 2019 · Annals of Oncology · 1.1K citations
Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments
Saife N. Lone, Sabah Nisar, Tariq Masoodi et al. · 2022 · Molecular Cancer · 722 citations
Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal
Thomas J. Mitchell, Samra Turajlic, Andrew Rowan et al. · 2018 · Cell · 533 citations
Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma
Holger Moch, Thomas Gasser, Mahul B. Amin et al. · 2000 · Cancer · 481 citations
Accurate histologic classification according to the new recommendations has implications because the prognostic importance of other histologic features that are of independent significance varies w...
Reading Guide
Foundational Papers
Start with Wheeler et al. (2013) for core molecular landscape of ccRCC including VHL/mTOR; follow with Moch et al. (2000) linking histologic subtypes to prognosis, establishing baseline before genomic era.
Recent Advances
Study Chen et al. (2016) for nine-subtype taxonomy; Mitchell et al. (2018) for clonal evolution; Escudier et al. (2019) guidelines integrating subtyping into treatment.
Core Methods
Core techniques: TCGA-style exome/RNA-seq for mutations (Wheeler 2013); multi-omics integration via methylation/copy number/RNA clustering (Chen 2016); phylogenetic tracing of clonal events (Mitchell 2018).
How PapersFlow Helps You Research Molecular Subtypes of Clear Cell Renal Cell Carcinoma
Discover & Search
PapersFlow's Research Agent uses searchPapers and exaSearch to query 'ccRCC molecular subtypes VHL mTOR', retrieving Wheeler et al. (2013) as top hit with 3433 citations, then citationGraph maps forward citations to Chen et al. (2016) taxonomy, and findSimilarPapers uncovers Mitchell et al. (2018) evolution study.
Analyze & Verify
Analysis Agent employs readPaperContent on Wheeler et al. (2013) to extract VHL mutation frequencies, verifies claims with CoVe against TCGA data, and runs PythonAnalysis with pandas to reanalyze subtype survival curves from Chen et al. (2016), graded via GRADE for high evidence quality in prognostic utility.
Synthesize & Write
Synthesis Agent detects gaps like subtype-TKI response predictors post-Wheeler et al. (2013), flags contradictions in histologic vs. molecular staging (Moch et al., 2000), while Writing Agent uses latexEditText, latexSyncCitations for Wheeler/Chen refs, and latexCompile to generate subtype diagrams via exportMermaid.
Use Cases
"Analyze survival data across ccRCC molecular subtypes from TCGA"
Research Agent → searchPapers('ccRCC TCGA subtypes') → Analysis Agent → readPaperContent(Wheeler 2013) + runPythonAnalysis(pandas survival curves) → statistical p-values and Kaplan-Meier plots.
"Draft review on ccRCC subtyping for precision oncology"
Synthesis Agent → gap detection(Wheeler/Chen papers) → Writing Agent → latexEditText(intro) → latexSyncCitations(3433 Wheeler cites) → latexCompile → PDF with mermaid subtype flowchart.
"Find code for ccRCC genomic classifier"
Research Agent → searchPapers('ccRCC classifier code') → Code Discovery → paperExtractUrls(Chen 2016) → paperFindGithubRepo → githubRepoInspect → runnable multilevel genomics script.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ ccRCC papers: searchPapers → citationGraph(Wheeler seed) → DeepScan 7-steps with CoVe checkpoints verifying subtype claims against Mitchell (2018). Theorizer generates hypotheses on subtype evolution from TRACERx data (Mitchell et al., 2018), chaining readPaperContent → runPythonAnalysis → synthesis.
Frequently Asked Questions
What defines molecular subtypes in ccRCC?
Subtypes arise from genomic profiling revealing VHL mutations, mTOR alterations, and methylation patterns classifying tumors into prognostic groups (Wheeler et al., 2013; Chen et al., 2016).
What methods classify ccRCC subtypes?
Multilevel approaches integrate DNA copy number, methylation, RNA-seq, and protein expression into taxonomies like the nine-subtype system (Chen et al., 2016); TCGA used exome sequencing for VHL/mTOR (Wheeler et al., 2013).
What are key papers on ccRCC subtyping?
Wheeler et al. (2013, 3433 citations) provides TCGA characterization; Chen et al. (2016, 372 citations) multilevel taxonomy; Mitchell et al. (2018, 533 citations) evolutionary tracing.
What open problems exist in ccRCC subtyping?
Challenges include intratumor heterogeneity resolution, subtype-therapy predictors, and clinical-grade classifiers beyond research cohorts (Mitchell et al., 2018; Chen et al., 2016).
Research Renal cell carcinoma treatment with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Molecular Subtypes of Clear Cell Renal Cell Carcinoma with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Renal cell carcinoma treatment Research Guide